Efficacy and safety of pralsetinib in Chinese advanced RET-mutant medullary thyroid cancer patients

医学 不利影响 甲状腺髓样癌 内科学 队列 肿瘤科 甲状腺癌 癌症 胃肠病学
作者
Xiangqian Zheng,Meiyu Fang,Yun Fan,Yuping Sun,Meili Sun,Ankui Yang,Bin Zhang,Qinjiang Liu,Hui Liu,Xiaohong Zhou,Tao Huang,Jianwu Qin,Zhaohui Wang,Mengmeng Qin,Zhenwei Shen,Sheng Yao,Jason Yang,Yu Wang,Ming Gao
出处
期刊:Endocrine-related Cancer [Bioscientifica]
卷期号:31 (4) 被引量:4
标识
DOI:10.1530/erc-23-0134
摘要

Pralsetinib has demonstrated efficacious activity in various solid tumors, including medullary thyroid cancer (MTC), as observed in the phase 1/2 global ARROW study (BLU-667-1101; NCT03037385). We evaluated the safety and efficacy of pralsetinib in Chinese patients with advanced RET -mutant MTC. In the extension cohort of ARROW, adult patients with advanced MTC, who had not received systemic therapy (except for cytotoxic chemotherapy), were treated with pralsetinib (400 mg once daily, orally). The primary endpoints were blinded independent central-reviewed (BICR) objective response rate (ORR) and safety. Between October 9, 2019, and April 29, 2020, 34 patients were enrolled at 12 centers across China. Among them, 28 patients tested positive for RET mutations in the central laboratory, and 26 of these, with measurable disease at baseline per BICR, were included in the analysis set for tumor response. As of April 12, 2021 (data cutoff), the ORR was 73.1% (95% CI: 52.2–88.4), and the median duration of response was not reached. The most common (≥15%) grade ≥3 treatment-related adverse events (TRAEs) in the 28 patients with RET -mutant MTC were neutrophil count decreased (8/28, 28.6%), blood creatine phosphokinase increased (6/28, 21.4%), and lymphocyte count decreased (5/28, 17.9%). Serious TRAEs were reported by six patients (21.4%), with the most common event being pneumonia (3/28, 10.7%). No patient discontinued treatment or died from pralsetinib-related adverse events. Pralsetinib demonstrated broad, deep, and durable efficacy, as well as a manageable and acceptable safety profile in Chinese patients with advanced RET -mutant MTC.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
朽木完成签到 ,获得积分10
刚刚
刚刚
fanyueyue应助111采纳,获得10
2秒前
2秒前
2秒前
kcmat发布了新的文献求助10
3秒前
hh完成签到,获得积分10
4秒前
Philadelphus发布了新的文献求助10
5秒前
einuo完成签到,获得积分10
5秒前
AKYDXS完成签到,获得积分10
8秒前
昏睡的蟠桃应助Llllll采纳,获得200
8秒前
科研通AI2S应助hao采纳,获得10
8秒前
9秒前
9秒前
香蕉觅云应助阿湫采纳,获得10
10秒前
星辰大海应助星辰采纳,获得10
10秒前
阿卡宁完成签到,获得积分10
10秒前
lzw完成签到 ,获得积分10
10秒前
沉静烧仙草完成签到,获得积分20
11秒前
烟花应助嘉嘉琦采纳,获得10
11秒前
隐形曼青应助科研通管家采纳,获得10
11秒前
Hello应助科研通管家采纳,获得10
12秒前
Ava应助科研通管家采纳,获得10
12秒前
上官若男应助科研通管家采纳,获得10
12秒前
12秒前
赘婿应助科研通管家采纳,获得10
12秒前
烟花应助科研通管家采纳,获得10
12秒前
FashionBoy应助科研通管家采纳,获得10
12秒前
英俊的铭应助科研通管家采纳,获得10
12秒前
在水一方应助科研通管家采纳,获得10
12秒前
accepted应助科研通管家采纳,获得10
12秒前
脑洞疼应助科研通管家采纳,获得10
12秒前
12秒前
cdh1994应助kcmat采纳,获得10
12秒前
我是老大应助科研通管家采纳,获得10
12秒前
乐乐应助科研通管家采纳,获得10
12秒前
FashionBoy应助科研通管家采纳,获得10
12秒前
12秒前
上官若男应助科研通管家采纳,获得10
12秒前
12秒前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
Research on Disturbance Rejection Control Algorithm for Aerial Operation Robots 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038524
求助须知:如何正确求助?哪些是违规求助? 3576221
关于积分的说明 11374737
捐赠科研通 3305912
什么是DOI,文献DOI怎么找? 1819354
邀请新用户注册赠送积分活动 892688
科研通“疑难数据库(出版商)”最低求助积分说明 815048